Regeneron Pharmaceuticals (REGN) Position Upped by Temasek Holdings Private Ltd; Sc Xii Management Stake in Mobileiron (MOBL) Has Cut by $12.77 Million as Shares Rose

November 15, 2017 - By wolcottdaily

Sc Xii Management Llc decreased its stake in Mobileiron Inc (MOBL) by 21.55% based on its latest 2017Q2 regulatory filing with the SEC. Sc Xii Management Llc sold 2.13 million shares as the company’s stock rose 12.63% with the market. The institutional investor held 7.75 million shares of the technology company at the end of 2017Q2, valued at $46.88 million, down from 9.88 million at the end of the previous reported quarter. Sc Xii Management Llc who had been investing in Mobileiron Inc for a number of months, seems to be less bullish one the $369.82 million market cap company. The stock decreased 1.28% or $0.05 during the last trading session, reaching $3.85. About shares traded. Mobileiron Inc (NASDAQ:MOBL) has risen 79.53% since November 15, 2016 and is uptrending. It has outperformed by 62.83% the S&P500.




Temasek Holdings Private Ltd increased its stake in Regeneron Pharmaceuticals (REGN) by 40.52% based on its latest 2017Q2 regulatory filing with the SEC. Temasek Holdings Private Ltd bought 51,202 shares as the company’s stock rose 21.24% with the market. The institutional investor held 177,553 shares of the health care company at the end of 2017Q2, valued at $87.20M, up from 126,351 at the end of the previous reported quarter. Temasek Holdings Private Ltd who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be bullish on the $41.34B market cap company. The stock decreased 2.24% or $8.82 during the last trading session, reaching $384.8. About 2,045 shares traded. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since November 15, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Among 10 analysts covering MobileIron (NASDAQ:MOBL), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. MobileIron had 21 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Mobileiron Inc (NASDAQ:MOBL) has “Buy” rating given on Tuesday, August 11 by Zacks. Sterne Agee CRT initiated Mobileiron Inc (NASDAQ:MOBL) on Tuesday, April 5 with “Buy” rating. RBC Capital Markets maintained Mobileiron Inc (NASDAQ:MOBL) rating on Friday, July 31. RBC Capital Markets has “Outperform” rating and $8 target. The firm has “In-Line” rating given on Wednesday, October 18 by Imperial Capital. The stock has “Buy” rating by Northland Capital on Wednesday, October 18. Goldman Sachs downgraded Mobileiron Inc (NASDAQ:MOBL) rating on Wednesday, September 9. Goldman Sachs has “Neutral” rating and $4.50 target. The rating was maintained by Northland Capital with “Buy” on Friday, July 14. Imperial Capital maintained Mobileiron Inc (NASDAQ:MOBL) rating on Thursday, May 12. Imperial Capital has “Outperform” rating and $4.50 target. Imperial Capital maintained it with “Outperform” rating and $5.50 target in Tuesday, February 9 report. As per Monday, September 19, the company rating was maintained by Morgan Stanley.

More notable recent Mobileiron Inc (NASDAQ:MOBL) news were published by: Businesswire.com which released: “SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of MobileIron, Inc.” on October 18, 2017, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” published on October 18, 2017, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 19, 2017. More interesting news about Mobileiron Inc (NASDAQ:MOBL) were released by: Fool.com and their article: “Why MobileIron, Inc. Stock Dropped Today” published on October 18, 2017 as well as Businesswire.com‘s news article titled: “IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of …” with publication date: October 19, 2017.

Investors sentiment increased to 1.88 in Q2 2017. Its up 0.20, from 1.68 in 2017Q1. It increased, as 14 investors sold MOBL shares while 18 reduced holdings. 22 funds opened positions while 38 raised stakes. 44.71 million shares or 0.70% more from 44.40 million shares in 2017Q1 were reported. Voya Mgmt accumulated 0% or 31,203 shares. Cubist Systematic Strategies Limited Liability Company has 0.01% invested in Mobileiron Inc (NASDAQ:MOBL). Northern Tru stated it has 0% in Mobileiron Inc (NASDAQ:MOBL). Shannon River Fund Ltd Liability reported 1.00 million shares. Great West Life Assurance Com Can holds 0% or 5,766 shares. Highbridge Cap Mngmt Ltd Company stated it has 0.01% in Mobileiron Inc (NASDAQ:MOBL). Schwab Charles Inv Incorporated holds 0% or 92,736 shares in its portfolio. The Ontario – Canada-based Royal Bancorporation Of Canada has invested 0% in Mobileiron Inc (NASDAQ:MOBL). California Employees Retirement Sys holds 0% or 14,800 shares in its portfolio. Vanguard Inc invested 0% in Mobileiron Inc (NASDAQ:MOBL). Grp One Trading Ltd Partnership has 0% invested in Mobileiron Inc (NASDAQ:MOBL) for 1,000 shares. Nationwide Fund holds 28,379 shares or 0% of its portfolio. Bank Of Montreal Can owns 26,362 shares. Deutsche Bancorporation Ag holds 0% of its portfolio in Mobileiron Inc (NASDAQ:MOBL) for 545,215 shares. Panagora Asset stated it has 0.01% of its portfolio in Mobileiron Inc (NASDAQ:MOBL).

Analysts await Mobileiron Inc (NASDAQ:MOBL) to report earnings on February, 6. They expect $-0.13 EPS, down 8.33% or $0.01 from last year’s $-0.12 per share. After $-0.17 actual EPS reported by Mobileiron Inc for the previous quarter, Wall Street now forecasts -23.53% EPS growth.

Among 30 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 14 have Buy rating, 1 Sell and 15 Hold. Therefore 47% are positive. Regeneron Pharmaceuticals Inc. had 97 analyst reports since July 28, 2015 according to SRatingsIntel. As per Tuesday, January 19, the company rating was upgraded by Roth Capital. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Hold” rating by Oppenheimer on Thursday, August 3. The stock has “Sell” rating by UBS on Wednesday, August 5. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Buy” rating by Brean Capital on Tuesday, March 8. The firm has “Market Perform” rating given on Thursday, November 9 by BMO Capital Markets. Chardan Capital Markets maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Friday, January 6. Chardan Capital Markets has “Neutral” rating and $345 target. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Outperform” rating by Wells Fargo on Friday, December 4. The company was initiated on Thursday, September 28 by Piper Jaffray. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Market Perform” rating given on Monday, June 26 by Bernstein. The company was initiated on Wednesday, June 29 by Bernstein.

More notable recent Regeneron Pharmaceuticals Inc (NASDAQ:REGN) news were published by: Fool.com which released: “Here’s Why Regeneron Pharmaceuticals Inc. Slipped 10% in October” on November 07, 2017, also Seekingalpha.com with their article: “Regeneron Pharmaceuticals (REGN) Q3 2017 Results – Earnings Call Transcript” published on November 08, 2017, Investorplace.com published: “Weak Quant Score Restrict Regeneron Pharmaceuticals (REGN) Rating” on November 13, 2017. More interesting news about Regeneron Pharmaceuticals Inc (NASDAQ:REGN) were released by: Fool.com and their article: “Is the stock a buy?” published on October 24, 2017 as well as Seekingalpha.com‘s news article titled: “Regeneron Falls On Q3 Report: Weighing The Pros And Cons” with publication date: November 13, 2017.

Since May 25, 2017, it had 1 insider purchase, and 6 insider sales for $44.10 million activity. VAGELOS P ROY sold $4.26 million worth of stock or 9,295 shares. The insider STAHL NEIL sold 8,567 shares worth $4.01M. GOLDSTEIN JOSEPH L sold $482,550 worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Friday, June 9. $65.06 million worth of stock was bought by Sanofi on Friday, June 2. Another trade for 2,000 shares valued at $948,890 was sold by BROWN MICHAEL S.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.